Pavese N - Search Results

1

Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study.

Pavese N, Khan NL, Scherfler C, Cohen L, Brooks DJ, Wood NW, Bhatia KP, Quinn NP, Lees AJ, Piccini P. Pavese N, et al. Mov Disord. 2009 Nov 15;24(15):2260-6. doi: 10.1002/mds.22817. Mov Disord. 2009. PMID: 19845000

2

Apomorphine test in de novo Parkinson's disease.

Bonuccelli U, Piccini P, Del Dotto P, Pavese N, D'Antonio P, Muratorio A. Bonuccelli U, et al. Among authors: pavese n. Funct Neurol. 1992 Jul-Aug;7(4):295-8. Funct Neurol. 1992. PMID: 1427361

3

White matter hyperintensities in Parkinson's disease. Clinical correlations.

Piccini P, Pavese N, Canapicchi R, Paoli C, Del Dotto P, Puglioli M, Rossi G, Bonuccelli U. Piccini P, et al. Among authors: pavese n. Arch Neurol. 1995 Feb;52(2):191-4. doi: 10.1001/archneur.1995.00540260097023. Arch Neurol. 1995. PMID: 7848130

4

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.

Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A. Piccini P, et al. Among authors: pavese n. J Neurol Neurosurg Psychiatry. 2000 May;68(5):589-94. doi: 10.1136/jnnp.68.5.589. J Neurol Neurosurg Psychiatry. 2000. PMID: 10766888 Free PMC article. Clinical Trial.

5

Dyskinesias following neural transplantation in Parkinson's disease.

Hagell P, Piccini P, Björklund A, Brundin P, Rehncrona S, Widner H, Crabb L, Pavese N, Oertel WH, Quinn N, Brooks DJ, Lindvall O. Hagell P, et al. Among authors: pavese n. Nat Neurosci. 2002 Jul;5(7):627-8. doi: 10.1038/nn863. Nat Neurosci. 2002. PMID: 12042822

6

Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study.

Khan NL, Brooks DJ, Pavese N, Sweeney MG, Wood NW, Lees AJ, Piccini P. Khan NL, et al. Among authors: pavese n. Brain. 2002 Oct;125(Pt 10):2248-56. doi: 10.1093/brain/awf237. Brain. 2002. PMID: 12244082

7

A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study.

Rakshi JS, Pavese N, Uema T, Ito K, Morrish PK, Bailey DL, Brooks DJ. Rakshi JS, et al. Among authors: pavese n. J Neural Transm (Vienna). 2002 Dec;109(12):1433-43. doi: 10.1007/s00702-002-0753-0. J Neural Transm (Vienna). 2002. PMID: 12486484 Clinical Trial.

8

Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.

Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, Robbins TW, Sahakian BJ, Dunnett SB, Piccini P. Pavese N, et al. Brain. 2003 May;126(Pt 5):1127-35. doi: 10.1093/brain/awg119. Brain. 2003. PMID: 12690052

9

Endogenous dopamine release after pharmacological challenges in Parkinson's disease.

Piccini P, Pavese N, Brooks DJ. Piccini P, et al. Among authors: pavese n. Ann Neurol. 2003 May;53(5):647-53. doi: 10.1002/ana.10526. Ann Neurol. 2003. PMID: 12730999

10

Cardiovascular effects of methamphetamine in Parkinson's disease patients.

Pavese N, Rimoldi O, Gerhard A, Brooks DJ, Piccini P. Pavese N, et al. Mov Disord. 2004 Mar;19(3):298-303. doi: 10.1002/mds.10651. Mov Disord. 2004. PMID: 15022183 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

206 results

Search Page

Filters